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Available online 4 April 2008Adolescence is a time of significant brain development, and exposure to nicotine during this
period is associated with higher subsequent rates of dependence. Chronic nicotine exposure
alters expression of nicotinic acetylcholine receptors (nAChRs), changing the pattern of
nicotine responsiveness. We used quantitative autoradiography to measure three major
subtypes of nAChRs after chronic nicotine exposure by osmotic minipump in adult and
periadolescent rats. Comparison of control animals at the two different ages revealed that
periadolescents express consistently greater numbersofα4β2⁎nAChRs compared to the same
brain regions of adults. Similar but less pronounced increases in α7 nAChRs were found in
control periadolescent rats compared to adults. Binding of [125I]α-conotoxin MII (largely to α6⁎
nAChRs) did not systematically differ between adults and periadolescents. The response to
chronic nicotine exposure also differed by age. Up-regulation ofα4β2⁎nAChRswasprominent
andwidespread inadult animals; in periadolescents,α4β2⁎up-regulation also occurred, but in
fewer regions and to a lesser extent. A similar pattern of responsewas seenwithα7 receptors:
adultsweremore responsive thanperiadolescents tonicotine-inducedup-regulation. In adult
animals, chronic nicotine exposure did not cause up-regulation of α6⁎ nAChRs; binding was
down-regulated in three regions. Unlike the other subtypes, the response of α6⁎ nAChRs to
chronic nicotine was greater in periadolescents, with more regions showing greater down-
regulation compared to adults. These differences in receptor expression and regulation
between age groups are likely to be important given theunique vulnerability of adolescents to
nicotine-induced behavioral changes and susceptibility to drug abuse.
© 2008 Elsevier B.V.Open access under CC BY-NC-ND license.Keywords:
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Autoradiography1. Introduction
Adolescence is the most common period for initiation of
recreational drug use (Spear, 2004). Such use often begins withmacology and Physiology, George Washington University Medical Center, 2300 I St. NW,
2870.
. Perry).
20Perry%20homepage.html (D.C. Perry).Widinylmethoxy)pyridine; α
CC BY-NC-ND license.tobacco products, and recent evidence suggests that adoles-
cents are particularly susceptible to the addictive and adverse
affects of tobacco smoke. Adolescent use of tobacco is
associated with subsequent higher daily consumption and a-CtxMII, α-conotoxin MII; nAChR, neuronal nicotinic acetylcholine
Table 1 – Levels of nicotine and cotinine in rat plasma and
brain after 2 weeks treatment
Plasma Brain
Nicotine,
µM
Cotinine,
µM
Nicotine,
µM
Cotinine,
µM
Adolescent 1.08±0.20 2.74±0.13 3.47±0.70 1.09±0.12
Adult 1.91±0.32 6.04±0.59 6.04±0.71 2.15±0.37
41B R A I N R E S E A R C H 1 2 1 5 ( 2 0 0 8 ) 4 0 – 5 2lower probability of smoking cessation (Chen andMillar, 1998).
Furthermore, there is a growing body of evidence suggesting
that smokers, particularly those who begin smoking during
adolescence, are more vulnerable to subsequent drug abuse
(Chambers et al., 2003; Adriani et al., 2006).
Adolescence is characterized by extensive physiological and
psychological development. Recent studieshaveshownthat the
human brain continues to develop through adolescence (Sowell
et al., 2003). There is a significant amount of brain growth in
early adolescence followed by a decrease in grey matter during
the transition from adolescence to adulthood, coincidingwith a
gradual loss of synapses and strengthening of remaining syn-
apses (Sowell et al., 2003). This occurs in several regions of the
brain and coincides with changes in complex social behaviors.
In rats, periadolescence has classically been defined as the
time between the earliest detection of diurnal gonadotropin
cycling (approximately postnatal day 28 [PN28]) and repro-Fig. 1 – Autoradiographic images of [125I]A-85380 binding toα4β2
four treatment groups. Binding of [125I]A-85380 (0.6 nM) was don
α6/α3* subtypes, and is shown in representative sections from f
C, periadolescent saline; D, periadolescent nicotine; E, non-speci
section. DLG, dorsal lateral geniculate nucleus; RSGb, retrosplenia
subiculum. Sections cut approximately −5.0 mm from bregma.ductive maturity (approximately PN38–42) (Spear and Brake,
1983). Neurochemical, neuroanatomical and behavioral
changes that occur during this period in rats are similar to
those seen in human adolescents (Spear and Brake, 1983;
Slotkin, 2002; Adriani et al., 2003).
Nicotine is the major neuroactive and addictive component
of tobacco smoke.Nicotine acts on pathways affecting neuronal
development and behavior, modulating anxiety, behavioral
inhibition, reward, and habit formation. Nicotine has been
demonstrated to cause long-lasting adverse effects on adoles-
cent rat brain, including altered proliferation, differentiation,
synaptic activity, synaptic maturation, and increased cell
damage and cell death (Trauth et al., 2000a; Slotkin, 2002;
Abreu-Villaca et al., 2003). Adolescent rats differ from adult rats
in their nicotine-induced behavioral responses (Belluzzi et al.,
2004; Adriani et al., 2003), and the effects of adolescent nicotine
exposure can persist into adulthood. Pre-exposure to nicotine
during, but not following, adolescence sensitizes rats tonicotine
effects on conditioned place preference and locomotion during
adulthood (Adriani et al., 2006). Also, several recent studies
(although not all; Kelley and Middaugh, 1999), have shown that
pretreatment with nicotine during adolescence sensitizes rats
to the rewarding effects of other drugs (Collins and Izenwasser,
2004; McMillen et al., 2005; McQuown et al., 2007).
Chronic exposure to nicotine, as well as smoking in humans,
iswell-knowntoalternumbersofnicotiniccholinergic receptors* nAChRs in rat brain sections from animals representing the
e in the presence of 100 nM α-CtxMII to block binding to
our treatment groups: A, adult saline; B, adult nicotine;
fic binding in the presence of 100 μM nicotine in an adjacent
l granular cortex; SNC, substantia nigra, pars compacta; Sub,
42 B R A I N R E S E A R C H 1 2 1 5 ( 2 0 0 8 ) 4 0 – 5 2(nAChRs) in brain, usually causing up-regulation. Receptor
regulation may contribute to behavioral effects of long-term
nicotine exposure, including tolerance and dependence.
Although extensive work has detailed the effects of chronic
nicotine exposure on different subtypes of nAChRs throughout
the adult rat brain, there have been relatively few studies of the
effects of such exposure on nAChRs in adolescent rat brain.
Wehavepreviouslyemployedthechronicnicotine treatment
protocol pioneered by Slotkin (2002) coupled with autoradio-
graphic methods to study the response of different subtypes of
nAChRs in rats (Nguyen et al., 2003; Nguyen et al., 2004;
Rasmussen and Perry, 2006; Perry et al., 2007). In the current
study, we extend this approach to compare the effects of adult
and adolescent chronic nicotine exposure. This method allows
simultaneous comparison of the effects on three major nAChR
subtypes, α4β2⁎, α7 andα6⁎, across awide range of brain regions.
We report distinct differences in the response to nicotine
between the two age groups, as well as differences in subtype
response. In addition, there were age-related differences in
receptor subtype expression seen in saline control animals.2. Results
The concentrations of nicotine and cotinine achieved in plasma
and brain are shown in Table 1. Based on the weight changesFig. 2 – Autoradiographic images of [125I]αBtx binding to α7 nAC
treatment groups. Binding of 0.72 nM [125I]αBtx is shown in repr
saline; B, adult nicotine; C, periadolescent saline; D, periadolesce
nicotine in an adjacent section. CA1, stratum oriens, hippocampu
SuG, superior colliculus, superficial grey layer; VLG, ventral later
from bregma.that occurred during the 14 day dosing period (+10% in adults,
+92% in adolescents), the nominal dose of free base nicotine
changed from6.0 to 3.1mg/kg/day inadolescents, and to 5.5mg/
kg/day in adults. Accordingly, by the end of the 14 day dosing
period, the plasma levels of both nicotine and its primary
metabolite cotinine in adult rats were higher than those found
inperiadolescent rats (1.8-fold fornicotine, 2.2-fold for cotinine).
A previous study using this same dosing protocol found
similar weight changes, but reported lower absolute plasma
levels of both compounds than found in this study, and found
a greater discrepancy between levels in adults and adoles-
cents (roughly 3–4 fold greater in adults) (Trauth et al., 2000b).
The levels of nicotine were higher in brain than in blood, and
were 2.2 times higher in adult brains compared to those of
periadolescents. Our results are consistent with a previous
study demonstrating that nicotine (but not cotinine) prefer-
entially accumulates in brain versus blood over continual
dosing regimens (Ghosheh et al., 2001).
Representative autoradiographic images are shown for
[125I]A-85380 binding in Fig. 1, for [125I]αBtx in Fig. 2, and for
[125I]α-CtxMII binding in Fig. 3. Each figure shows total binding
in equivalent regions from each of the four treatment groups:
A, adult saline; B, adult nicotine; C, periadolescent saline; D,
periadolescent nicotine. Non-specific binding in a section
adjacent to one of the four total binding sections is shown in E.
Adjacent sections from the same animals are shown acrosshRs in rat brain sections from animals representing the four
esentative sections from four treatment groups: A, adult
nt nicotine; E, non-specific binding in the presence of 100 μM
s; DEn, endopiriform nucleus; PoDG, posterior dentate gyrus;
al geniculate nucleus. Sections cut approximately −5.0 mm
Fig. 3 – Autoradiographic images of [125I]α-CtxMII binding to α6* nAChRs in rat brain sections from animals representing
the four treatment groups. Binding of 0.8 nM [125I]α-CtxMII is shown in representative sections from four treatment groups:
A, adult saline; B, adult nicotine; C, periadolescent saline; D, periadolescent nicotine; E, non-specific binding in the presence of
100 μM nicotine in an adjacent section. DLG, dorsal lateral geniculate nucleus; opt, optic tract; SuG, superior colliculus,
superficial grey layer; VLG, ventral lateral geniculate nucleus. Sections cut approximately −5.0 mm from bregma.
43B R A I N R E S E A R C H 1 2 1 5 ( 2 0 0 8 ) 4 0 – 5 2the three figures (e.g. 1A, 2A and 3A are all from the same adult
saline-treated rat).
A-85380has been shown to bind selectively toβ2-containing
nAChRs (Sullivan et al., 1996). The concentration of α-CtxMII
included in the incubation (100 nM) should effectively block
binding to α6β2⁎ (Whiteaker et al., 2000; Champtiaux et al.,
2002). The affinity of α-CtxMII at α3β2⁎ sites may be somewhat
lower (Gotti et al., 2006) and the affinity at α2β2⁎ sites is
presently unknown.Wewill refer to the binding of [125I]A-85380
under these conditions as α4β2⁎, with the understanding that
there may also be small contributions in some regions from
these other two relatively minor subtypes. Visual evidence of
up-regulated α4β2⁎ binding is apparent in adults by comparing
Figs. 1A and B; in contrast, up-regulation of α4β2⁎ binding in
periadolescents is not as readily apparent by visual inspection
of Figs. 1C and D.
[125I]αBtx labeling is widespread in mammalian brain, and
is thought to be limited largely or entirely to α7 homomers.
Similar distributions in adult and periadolescent brains are
seen in Fig. 2. Although some regions express high levels of
both α4β2⁎ and α7 nAChRs (e.g. superior colliculus, cerebral
cortex), overall the pattern of α7 binding is very different than
that of α4β2⁎, with relatively high densities in hippocampus,
amygdala and hypothalamus, and lower levels in striatum
and thalamus compared to α4β2⁎.At the concentration employed, [125I]α-CtxMII binding is
selective forα6β2⁎nAChRs (Whiteaker et al., 2000; Champtiaux
et al., 2002). Although α-CtxMII was originally described in
functional studies as selective for α3β2⁎ nAChRs (Cartier et al.,
1996), recent evidence suggests that the binding affinity is in
the order of 50 nM (Gotti et al., 2006), which means that there
would be very little contribution from α3β2⁎ nAChRs in these
studies, given the concentration of radioligand employed.
Therefore, we will refer to the sites labeled by [125I]α-CtxMII
under the conditions employed here as α6⁎ nAChRs. α6⁎
nAChRs are expressed in visual systems from the retina to
the superior colliculus, and in dopamine systems in rat brain
(Whiteaker et al., 2000; LeNovere et al., 1996; Champtiaux et al.,
2002). This distribution is reflected in the images shown in
Fig. 3, for both adult and periadolescent brains. No differences
with nicotine treatment are readily apparent from comparing
images.
Binding was quantified by digital densitometry. Means of
[125I]A-85380 binding to α4β2⁎ receptors in 38 brain regions for
the four treatment groups are shown in Table 2 (note that the
individual images shown here may not always reflect the
quantitative results obtained by densitometry across multiple
images). Comparison of binding in adult versus periadolescent
saline-treated controls reveals a distinct age effect: bindingwas
uniformly higher in periadolescents. The mean binding across
Table 2 – Binding (fmol) of [125I]A-85380 in the presence of 100 nM α-CtxMII (to α4β2* nAChRs)
Adults Periadolescents Treatment effects Age effectsBrain region
Saline Nicotine Saline Nicotine % chg from saline % chg from adult
Mean±sem Adult Periadol. Saline Nicotine
1 Nucleus accumbens, core 3.10±0.35 5.16±0.43 5.48±0.62 7.05±0.51 66.4⁎⁎ 28.5⁎ 76.8⁎⁎ 36.5⁎
2 Nucleus accumbens, shell 2.72±0.33 5.08±0.46 5.22±0.64 7.16±0.49 86.7⁎⁎ 37.2⁎ 91.8⁎⁎ 40.9⁎
3 Endopiriform nucleus 3.91±0.33 7.48±0.30 5.92±0.68 8.32±0.22 91.1⁎⁎⁎ 40.4⁎⁎ 51.4⁎⁎ 11.3
4 Striatum, rostral 3.94±0.39 5.97±0.41 6.09±0.59 7.87±0.30 51.4⁎ 29.2⁎ 54.8⁎⁎ 31.8⁎
5 Striatum, caudal 3.39±0.35 5.36±0.50 5.40±0.66 7.13±0.48 58.3⁎⁎ 32.1⁎⁎ 59.2⁎⁎ 32.9
6 Lateral septum 3.65±0.37 5.20±0.56 6.00±0.63 7.25±0.47 42.6⁎ 20.8 64.6⁎⁎ 39.5⁎
7 Medial habenula 8.14±0.26 8.49±0.15 8.70±0.04 8.57±0.13 4.3 −1.5 6.9 0.9
8 Fasciculus retroflexus 6.02±0.36 6.96±0.32 7.66±0.35 8.19±0.25 15.6 6.9 27.2⁎⁎ 17.7⁎
9 Posterior hypothalamus 1.29±0.18 4.38±0.65 2.06±0.32 5.41±0.71 239⁎⁎ 162⁎⁎⁎ 59.4 23.3
10 Ventral posterior thalamic
nucleus
6.12±0.44 8.21±0.32 7.54±0.41 8.50±0.21 34.2⁎⁎ 12.8 23.2⁎ 3.5
11 Posterior thalamic nucleus
group
6.91±0.41 8.46±0.24 8.08±0.27 8.63±0.13 22.4⁎⁎ 6.8 16.9⁎⁎ 2.0
12 Lateral posterior thalamic
nucleus
7.14±0.37 8.32±0.27 8.14±0.26 8.59±0.14 16.6⁎ 5.6 14.1⁎ 3.3
13 Internal capsule 1.52±0.17 2.32±0.33 4.12±0.71 4.82±0.66 52.6 16.8 171⁎ 107
14 Optic tract 1.92±0.20 2.00±0.32 4.58±0.87 5.28±0.63 4.6 15.2 139⁎⁎ 163⁎
15 Optic chiasm 5.88±0.45 6.98±0.39 7.43±0.44 8.16±0.28 18.7 9.9 26.4⁎ 16.9⁎⁎
16 Superior colliculus,
superficial grey
6.11±0.54 7.29±0.30 7.56±0.42 8.09±0.32 19.5 7.0 23.7 10.8⁎
17 Dorsal lateral geniculate 7.91±0.27 8.78±0.04 8.47±0.15 8.65±0.12 11.0 2.2 7.1 −1.4
18 Ventral lateral geniculate 5.67±0.60 6.32±0.30 6.70±0.59 7.71±0.46 11.5 15.1 18.2⁎ 22.2
19 Medial geniculate 6.24±0.45 8.07±0.22 7.71±0.39 8.39±0.23 29.3⁎⁎ 8.9 23.4⁎⁎ 4.0
20 Zona incerta 2.44±0.29 5.84±0.67 4.63±0.66 6.96±0.55 140⁎⁎ 50.2⁎ 90.0⁎⁎ 19.1
21 Tectal nuclei 5.44±0.56 6.02±0.30 6.72±0.52 7.46±0.47 10.7⁎ 11.1 23.6⁎⁎ 24.1
22 Substantia nigra, pars compacta 6.07±0.75 7.44±0.55 8.06±0.26 8.31±0.28 22.6 3.0 32.8 11.6
23 Ventral tegmental area 4.88±0.60 6.05±0.56 6.89±0.52 7.99±0.32 24.1⁎ 16.1 41.3⁎ 32.2
24 Dentate gyrus, hippocampus 2.35±0.31 5.00±0.61 4.27±0.62 7.09±0.44 112⁎⁎ 66.0⁎ 81.5⁎ 41.8
25 CA1, hippocampus 1.21±0.13 3.29±0.48 2.29±0.37 5.06±0.68 171⁎⁎ 120⁎⁎ 89.1⁎ 53.7
26 Subiculum 3.61±0.42 4.93±0.29 5.79±0.62 6.52±0.56 36.5⁎ 12.7 60.2⁎ 32.3
27 Postsubiculum 7.23±0.37 8.25±0.16 8.37±0.18 8.60±0.14 14.1⁎⁎ 2.8 15.7⁎⁎ 4.3
28 Pontine nucleus 2.40±0.47 3.98±0.44 4.11±0.77 5.99±0.67 66.1 45.6 71.7⁎ 50.5
29 Entorhinal cortex 3.01±0.37 6.50±0.24 5.15±0.70 7.33±0.50 116⁎⁎ 42.3⁎ 71.1⁎⁎ 12.8
30 Frontal cortex, L4 4.08±0.40 6.59±0.50 6.04±0.59 7.83±0.38 61.6⁎⁎ 29.7⁎ 48.1⁎⁎ 18.9
31 Frontal cortex, L5 3.10±0.32 6.70±0.38 5.20±0.66 7.58±0.44 116⁎⁎⁎ 45.6⁎ 67.9⁎⁎ 13.0
32 Cingulate cortex, outer 5.48±0.40 7.09±0.36 7.35±0.46 8.19±0.28 29.3⁎⁎ 11.4 34.3⁎⁎ 15.6
33 Cingulate cortex, inner 4.89±0.43 7.13±0.38 6.91±0.54 8.45±0.16 45.9⁎⁎ 22.2 41.4⁎⁎ 18.5
34 Retrosplenial cortex, L1–2 6.79±0.41 8.04±0.18 8.07±0.33 8.57±0.14 18.4⁎⁎ 6.2 18.8⁎⁎ 6.6
35 Retrosplenial cortex, L3–4 6.36±0.44 7.93±0.18 7.93±0.37 8.44±0.19 24.7⁎⁎ 6.5 24.6⁎⁎ 6.5
36 Visual cortex, L4 4.95±0.50 7.54±0.31 6.70±0.61 8.11±0.32 52.4⁎⁎ 21.0 35.5⁎ 7.6
37 Visual cortex, L5 3.42±0.44 6.44±0.53 5.60±0.68 7.72±0.42 88.0⁎⁎⁎ 37.9⁎ 63.4⁎⁎ 19.8
38 Visual cortex, L6 4.47±0.44 6.73±0.32 6.53±0.63 7.87±0.37 50.7⁎⁎ 20.5 46.1⁎⁎ 16.9
Means determined from 5–8 replicates. Means from all four groups compared by 2-way ANOVA with Holm–Sidak post-test; ⁎p<0.05;
⁎⁎p<0.01; ⁎⁎⁎p<0.001.
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regions demonstrating significantly higher binding in the
younger rats. The comparison of binding in saline controls for
adults and adolescents is presented graphically in Fig. 4,
demonstrating the age effects: adolescent binding as a percent
of that in theadult.A similar but less pervasivepatternwas seen
when comparing nicotine-treated adults and periadolescents:
higher binding in younger rats. As reported in previous studies,
there was widespread up-regulation of α4β2⁎ binding in adult
rats: the average binding across 38 regionswas 55% higher after
nicotine treatment, and 28 of 38 regions showed a statisticallysignificant increase (none were lower). The increases in α4β2⁎
binding with chronic nicotine were not uniform across regions:
large and consistent increases were detected across cerebral
cortex, and inmany forebrain regions andhippocampus; effects
were much more varied in diencephalon and midbrain struc-
tures. The effect of nicotine exposure on α4β2⁎ receptors in
periadolescents was noticeably smaller. The average binding
across 38 regions was 27% higher after nicotine treatment, and
only 13 of 38 regions showed a statistically significant increase
(none were significantly decreased). The increase was larger in
adults than in periadolescents for 35 of the 38 regions (for the
Fig. 4 – Ageeffects: Binding to threenAChRsubtypes compared in saline controls fromadults andperiadolescent rats. Binding in
periadolescent brains is shown as a percent of that in the equivalent brain region in the adult animal; the 100% line
indicateswhere bindingwould be if itwas equal in adults andperiadolescents. Numbers refer to specific brain regions identified
in Table 1 (for α4β2* nAChRs), Table 2 (for α7 nAChRs) or Table 3 (for α6* nAChRs). Different from binding in the equivalent
brain region in adults: *p<0.05; **p<0.01; ***p<0.001; 2-way ANOVA with Holm–Sidak post-test.
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significant).
The treatment effects of nicotine on binding in adults and
adolescents is presented graphically in Fig. 5, showing binding
in nicotine-treated animals as a percent of that in saline-
treated animals. To obtain amore global sense of the effects of
age and treatment on α4β2⁎ binding, we performed GLM
analysis on the means collapsed across all regions measured.
There was no interaction between age and treatment (F=0.17;
p=0.6861). The overall effects of age (F=11.45; p=0.0021) and
nicotine treatment (F=11.37; p=0.0022) were both highly
significant for binding to the α4β2⁎ nAChR.
Comparison of α7 binding in adult versus periadolescent
saline-treated controls reveals similar but less dramatic age-
related differences (Table 3; Fig. 4). The mean binding across
all 40 regionswas 15%higher in saline-treated periadolescents
compared to saline-treated adults, with 12 of 40 regions
measured demonstrating significantly higher binding in the
younger rats (none were significantly lower in periadoles-
cents). For nicotine-treated animals, there was overall no
difference between older and younger rats: two regions weresignificantly higher in periadolescents, while three were
significantly lower. As previously reported, chronic nicotine
also causes up-regulation of α7 binding in adult rats (Rasmus-
sen and Perry, 2006) and mice (Pauly et al., 1991) although to a
lesser degree and in fewer regions than occurs with α4β2⁎
nAChRs. Across all 40 regions, there was a mean binding
increase of 36% in adult rats, with 20 of 40 regions demon-
strating significant increases; no region showed significantly
lower binding after nicotine (Table 3; Fig. 5). Up-regulationwas
most prominent in cerebral cortex, with several regions also
up-regulated in hippocampus, hypothalamus and amygdala.
As with α4β2⁎, the nicotine effect was much smaller in
periadolescents. The mean increase was 16%, and only 10 of
40 regions showed significant increases (none showed sig-
nificant decreases). To obtain a more global sense of the
effects of age and treatment on α7⁎ binding, we performed
GLM analysis on the means collapsed across all regions
measured. There was no interaction between age and treat-
ment (F=2.32; p=0.1402). The overall effect of age was not
significant (F=2.41; p=0.1334), but the overall effect of nicotine
treatment was significant (F=9.62; p=0.0047).
Fig. 5 – Treatment effects: binding to three nAChR subtypes in adult and periadolescent rat brains. Binding in nicotine-treated
animals is shown as a percent of that in the equivalent brain region in the saline-treated animals, for both adults (top three
graphs) and periadolescents (bottom three graphs). The 100% line indicates where the binding would be if it was unaffected by
nicotine treatment. Left two graphs show binding to α4β2* nAChRs; middle two graphs show binding to α7 nAChRs; right
two graphs show binding to α6* nAChRs. Numbers on Y-axis refer to specific brain regions identified in Table 1 (for α4β2*),
Table 2 (for α7) or Table 3 (for α6*). Different from binding in the equivalent brain region in saline controls: *p<0.05; **p<0.01;
***p<0.001; 2-way ANOVA with Holm–Sidak post-test.
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Table 3 – Binding (fmol) of [125I]α-bungarotoxin (to α7 nAChRs)
Adults Periadolescents Treatment
effects
Age effectsBrain region
Saline Nicotine Saline Nicotine %chg from saline % chg from adult
Mean±sem Adult Periadol. Saline Nicotine
1 Striatum 1.51±0.46 1.70±0.43 1.58±0.24 2.04±0.17 12.6 29.4 4.5 20.0
2 Nucleus accumbens 1.78±0.48 2.35±0.64 1.99±0.27 2.36±0.55 32.5 18.3 12.1 0.1
3 Septum 6.03±1.04 7.90±1.34 7.43±0.63 7.97±1.07 31.0⁎⁎ 7.2 23.2⁎ 0.8
4 Nucleus vertical limb diag. band 5.65±0.93 6.47±0.99 5.79±0.19 6.43±0.52 14.6 11.2 2.5 −0.6
5 Ventral pallidum 3.79±1.01 4.06±1.07 3.45±0.47 4.74±1.37 7.0 37.6 −9.1 16.9
6 Endopiriform nucleus 10.7±1.99 16.7±3.59 14.5±1.39 16.9±0.92 55.6⁎⁎⁎ 15.9 35.7⁎ 1.1
7 Bed nucleus, stria terminalis 5.77±0.86 9.29±2.75 6.58±0.50 6.50±0.77 61.1⁎⁎ −1.1 14.1 −30.0⁎
8 Anterior hypothalamus 9.67±2.52 13.5±2.86 9.79±1.61 7.47±1.01 39.5⁎ −23.7 1.3 −45.0⁎
9 Supraoptic nucleus hypothalamus 26.1±3.67 35.6±14.5 18.5±1.43 21.9±0.36 36.7 18.4 −29.2 −38.6
10 Posterior hypothalamus 12.3±2.87 16.4±1.24 12.0±1.99 15.9±2.68 34.0⁎⁎ 32.8⁎ −2.4 −3.2
11 Lateral hypothalamus 4.85±1.35 7.03±1.44 5.23±0.33 6.54±1.43 44.9 24.9 7.8 −7.1
12 Ventromedial hypothalamus 13.0±3.40 17.9±4.94 13.7±2.42 15.7±2.92 37.9 14.4 5.4 −12.6
13 Zona incerta 3.84±1.16 6.18±0.87 4.95±0.23 6.08±0.58 60.9⁎⁎⁎ 22.7 29.0⁎ −1.6
14 Subthalamic nucleus 20.4±10.39 27.8±3.05 20.5±2.70 30.9±4.75 36.5 50.9 0.5 11.0
15 Lateral amygdaloid nuclei 5.23±0.58 9.56±1.33 6.68±1.01 8.70±1.59 82.9⁎⁎⁎ 30.2⁎ 27.8⁎ −9.0
16 Basal amygdaloid nuclei 17.7±2.74 28.2±4.61 20.7±0.90 26.1±1.88 59.1⁎⁎⁎ 26.0⁎ 16.6 −7.6
17 Posteromedial cortical amygdala 19.3±4.70 28.2±5.93 17.5±2.65 23.4±4.65 46.4⁎⁎ 33.6⁎ −9.0 −17.0
18 Amygdalohippocampal area 18.1±1.11 24.9±5.08 19.4±0.88 23.8±0.92 38.0⁎⁎ 22.6 7.2 −4.7
19 Stratum oriens, hippocampus 7.58±1.23 9.28±2.11 8.57±0.64 8.26±0.98 22.5 −3.5 13.0 −11.0
20 S. lac.-molec., hippocampus 5.55±0.44 7.12±1.11 6.79±0.51 7.20±1.40 28.4 6.0 22.5 1.1
21 Dentate gyrus, hippocampus 11.3±1.46 18.9±1.77 11.4±1.82 13.9±2.47 66.8⁎ 22.1 0.6 −26.0⁎
22 Ventral CA1, hippocampus 6.18±0.80 10.9±0.93 11.1±1.43 13.1±1.80 77.2⁎⁎⁎ 18.4 79.1⁎⁎⁎ 19.6
23 Posterior dentate gyrus 58.8±12.38 66.9±13.6 74.5±8.03 77.8±7.45 13.8 4.5 26.7 16.4
24 Parasubiculum 15.1±2.89 19.6±2.96 14.6±2.96 16.3±1.65 29.8 11.8 −3.1 −16.6
25 Tectal nuclei 8.41±0.22 11.7±1.40 12.4±0.82 13.0±1.69 38.5⁎⁎ 4.9 47.6⁎⁎⁎ 11.8
26 Ventral lateral geniculate 11.1±1.57 13.9±0.89 15.1±1.34 15.7±2.13 25.2⁎⁎ 4.0 35.7⁎⁎⁎ 12.7
27 Superior colliculus, superficial grey 19.7±2.83 22.4±2.34 19.1±2.70 22.2±1.46 14.2 16.1 −2.7 −1.1
28 Superior colliculus, optic L 11.4±1.81 13.4±0.90 11.9±1.19 11.8±1.19 16.8 −0.7 3.8 −11.7
29 Mammillary nucleus 19.5±1.23 23.2±1.56 23.1±3.15 25.5±3.05 18.9⁎ 10.3 18.7⁎ 10.1
30 Dorsal raphe nucleus 11.7±2.78 13.5±0.73 11.0±1.08 12.0±1.06 15.0 8.9 −6.3 −11.3
31 Parabigeminal nucleus 15.4±2.46 17.7±1.49 17.0±1.50 14.3±2.16 14.8 −16.1 10.7 −19.1
32 Microcellular tegmental nucleus 12.3±2.43 14.2±2.10 13.6±2.73 12.9±1.68 16.1 −5.3 11.2 −9.3
33 Frontal cortex, inner laminae 5.76±0.49 8.20±1.31 6.72±0.46 9.84±1.24 42.4⁎⁎⁎ 46.4⁎⁎ 16.6⁎ 19.9⁎
34 Frontal cortex outer laminae 3.73±0.59 5.08±0.66 3.96±0.41 5.35±0.72 36.0⁎⁎ 35.1⁎⁎ 6.2 5.4
35 Cingulate cortex, lateral 6.02±0.75 8.34±1.16 6.79±0.20 8.99±1.11 38.7⁎⁎⁎ 32.4⁎ 12.9 7.8
36 Cingulate cortex, medial 4.79±0.82 6.64±0.87 5.24±0.20 6.23±0.43 38.7⁎⁎⁎ 18.8⁎ 9.4 −6.2
37 Visual cortex, inner laminae 3.15±0.15 4.61±0.37 4.50±0.59 5.77±1.21 46.3⁎⁎ 28.5⁎ 42.6⁎⁎ 25.2⁎
38 Visual cortex, outer laminae 3.92±0.42 6.11±0.58 6.14±0.70 7.41±1.13 55.7⁎ 20.6⁎ 56.5⁎ 21.3
39 Retrosplenial cortex 5.18±0.67 5.64±0.43 6.76±0.48 6.56±0.90 9.0 −3.0 30.6⁎⁎ 16.2
40 Entorhinal cortex 10.4±1.41 13.5±2.14 11.4±1.52 12.7±1.83 29.3⁎⁎ 10.8 9.5 −6.1
Means determined from 5–8 replicates. Means from all four groups compared by 2-way ANOVA with Holm–Sidak post-test; ⁎p<0.05; ⁎⁎p<0.01;
⁎⁎⁎p<0.001.
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periadolescent saline-treated controls did not show system-
wide age-related differences (Table 4; Fig. 4): themean binding
across 15 regions in periadolescents was 2% higher than in
adults. Two regions (optic chiasm, optic tract) were signifi-
cantly greater in periadolescents, while three (caudal striatum,
dorsal lateral geniculate, superior colliculus)were significantly
lower. The comparison across age in nicotine-treated animals
showed that six regions were significantly lower in periado-
lescents,while onewas higher (optic tract). In contrast to α4β2⁎
and α7 nAChRs, autoradiographic studies have found that
chronic nicotine causes either no change or a decrease in
binding to α6⁎ nAChRs (Perry et al., 2007; Mugnaini et al., 2006;Lai et al., 2005). In the current studies we also found a trend
towards decreased binding with chronic nicotine exposure: a
5% average decrease across 15 regions; binding was signifi-
cantly decreased in three regions, increased in none (Table 4;
Fig. 5). In contrast to the other two nAChR subtypes, the effect
of chronic nicotine was more pronounced in periadolescents
than adults: across all 15 regions, therewas ameandecrease of
21%, and six of 15 regions in periadolescents showed a
significant decrease with nicotine exposure. To obtain a more
global sense of the effects of age and treatment on α6⁎ binding,
we performed GLM analysis on the means collapsed across all
regions measured. There was no significant interaction
between age and treatment (F=3.68; p=0.0653). The overall
Table 4 – Binding (fmol) of [125I]α-conotoxin MII (to α6* nAChRs)
Adults Periadolescents Treatment effects Age effectsBrain region
Saline Nicotine Saline Nicotine %chg from saline % chg from adult
Mean±sem Adult Periadol. Saline Nicotine
1 Nucleus accumbens, shell 0.11±0.01 0.11±0.01 0.12±0.03 0.11±0.02 +7.3 −2.2 +7.3 +0.1
2 Nucleus accumbens, core 0.19±0.03 0.16±0.02 0.21±0.05 0.14±0.02 −13.0 −33.0 +15.3 −11.1
3 Striatum, rostral 0.21±0.02 0.19±0.02 0.29±0.05 0.17±0.02 −10.3 −43.1 +38.7 −11.9
4 Striatum, caudal 0.31±0.02 0.22±0.03 0.20±0.03 0.11±0.02 −27.2⁎ −43.8⁎ −33.3⁎ −48.9⁎
5 Olfactory tubercle 0.14±0.03 0.14±0.02 0.15±0.03 0.14±0.05 −2.7 −8.9 +7.0 +0.2
6 Optic chiasm 1.64±0.04 1.84±0.15 2.27±0.06 2.11±0.17 +11.6 −7.3 +38.2⁎⁎ +14.7
7 Optic tract 1.84±0.07 1.69±0.08 2.42±0.09 2.19±0.06 −8.1 −9.5⁎ +31.6⁎⁎⁎ +29.7⁎⁎⁎
8 Medial habenula 0.26±0.03 0.31±0.05 0.14±0.04 0.14±0.04 +19.9 −1.8 −45.1 −55.1⁎
9 Fasciculus retroflexus 0.40±0.05 0.42±0.06 0.38±0.03 0.30±0.03 +4.3 −22.3 −4.1 −28.5
10 Ventral tegmental area 0.28±0.04 0.32±0.03 0.26±0.02 0.15±0.01 +16.9 −43.0⁎ −4.4 −53.4⁎⁎⁎
11 Substantia nigra, pars compacta 0.28±0.05 0.29±0.05 0.32±0.03 0.17±0.01 +2.1 −47.4⁎ +11.4 −42.6⁎⁎
12 Tectal nuclei 1.82±0.13 1.75±0.07 1.92±0.17 1.76±0.17 −3.9 −8.3 +5.5 +0.7
13 Dorsal lateral geniculate 1.95±0.07 1.66±0.08 1.73±0.07 1.43±0.05 −15.1⁎ −17.1⁎⁎ −11.6⁎ −13.7
14 Ventral lateral geniculate 1.84±0.12 1.26±0.11 1.56±0.13 0.84±0.08 −31.8⁎⁎ −46.4⁎⁎⁎ −15.4 −33.5⁎
15 Superior colliculus, superficial grey 3.27±0.14 3.18±0.14 2.88±0.10 2.97±0.06 −2.9 +2.8 −12.1⁎ −6.6
Means determined from 5–8 replicates. Means from all four groups compared by 2-way ANOVA with Holm–Sidak post-test; ⁎p<0.05; ⁎⁎p<0.01;
⁎⁎⁎p<0.001.
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overall effect of nicotine treatment was significant (F=3.68;
p=0.0044).3. Discussion
These results demonstrate the first comprehensive character-
ization of the three major nAChR subtypes in adolescent and
adult rat brain, and the first direct comparison of their
differential response to chronic nicotine treatment in multiple
brain regions. These data demonstrate that adolescent and
adult rats exhibit distinct differences in the numbers of α4β2⁎
nAChRs, and to a lesser extent α7 nAChRs, throughout the
brain; however, α6⁎ nAChRs are largely similar at both ages.
Furthermore, the response of these receptors to chronic
nicotine also differs by age: up-regulation of α4β2⁎ and α7
receptors was greater in adults, but down-regulation of α6⁎
receptors was greater in adolescents.
Developmental differences in nAChR expression have been
reported in a few previous studies. Leslie et al. reported
differences between PN20 and adult rats in expression of
midbrain nAChR subunit mRNA (Azam et al., 2007). They
found a gradual decline of midbrain [3H]nicotine binding after
birth (although no significant differences were detected
between adults and adolescents); midbrain [125I]α-Btx binding
remained constant throughout development (Azam et al.,
2007). [3H]cytisine binding was reported to be higher in
cerebral cortex and hippocampus but not in midbrain of
PN45 rats compared to PN60 or PN75 rats (Trauth et al., 1999).
A recent autoradiographic study in mice found that [3H]
cytisine and [3H]epibatidine binding tended to peak devel-
opmentally at PN21 before declining to adult levels, while
[125I]α-Btx binding peaked earlier at PN10, before also declining
to adult levels (Yu et al., 2007). Our results are generally
consistent with these studies, and extend them by directly
comparing the three major nAChR subtypes at both ages.Age differences in nAChR function have also been reported.
Nicotine-stimulated 86Rb efflux was found to be higher in four
brain regions in PN35 rats compared to PN28 or PN63 rats
(Britton et al., 2007). This method measures primarily pre-
synaptic nAChRs, and is mostly limited to α4β2⁎ (Marks et al.,
1999). These results are consistent with our findings that α4β2⁎
bindingwas significantly higher in periadolescent rats (PN42) in
most areas sampled from these four brain regions, suggesting
that this adolescent “peak” response is the result of increased
receptor expression. Nicotine-stimulated striatal dopamine
release was found to be greater in PN30 compared to PN40 or
adult rats (Azam et al., 2007). In vivo microdialysis studies
showed that adult rats responded to anacutenicotine challenge
with an increase in extracellular striatal dopamine, whereas
adolescent rats did not exhibit significant increases to such a
challenge (Badanich and Kirsteina, 2004). Nicotine-stimulated
dopamine release from invitro striatal preparations ismediated
both by α4β2⁎ and α6⁎ receptors located on dopamine terminals
(Salminen et al., 2004; Perry et al., 2007), whereas in vivo,
nicotine-stimulated dopamine release is largely mediated by
α4β2⁎ receptors (Champtiauxetal., 2003).Overallwe foundmore
α4β2⁎ receptors in both dopamine cell body and terminal
regions inadolescents compared to adults, but nonet difference
in α6⁎ receptors. This difference in the balance between these
two subtypes may contribute to an enhanced sensitivity to the
rewarding effects of nicotine in adolescents.
Nicotine has long been known to cause up-regulation of its
receptors following chronic administration. Oneprevious study
directly compared nicotine's effects on nAChRs in adults and
adolescents, using the same treatment protocol. Up-regulation
of [3H]cytisinebinding (largely toα4β2⁎nAChRs)wasdetected in
midbrain,hippocampusandcerebral cortexof bothadolescents
and adults, but differenceswere seen in regional specificity and
persistence (Trauth et al., 1999). Up-regulation varied by region
in adults but was uniform in adolescents; in addition,
adolescent up-regulation showed greater persistence (Trauth
et al., 1999). Direct comparison with the present results is
49B R A I N R E S E A R C H 1 2 1 5 ( 2 0 0 8 ) 4 0 – 5 2difficult given their use of homogenate binding, and the
different time points employed. Similar to their findings, we
saw greater increases in α4β2⁎ binding in adult hippocampal
regions compared to adolescents. We saw only modest and
often non-significant increases in midbrain structures, in both
age groups. As for the greater regional variability of response in
adults, this is difficult to quantify; instead, we found an overall
much greater responsiveness of adult α4β2⁎ binding to up-
regulation by nicotine.
Relatively less attention has been paid to the non-α4β2
nAChRs in adolescents, in part due to the paucity of selective
tools. One study used homogenate binding to demonstrate
modest up-regulation of [125I]α-Btx binding in the striatumand
brainstem of periadolescent rats (Slotkin et al., 2004). They
noted that previous studies failed to detect up-regulation in
adults, and concluded that this represented a developmental
difference. However, none of the studies cited used the dosing
regimen employed in their study, which was the same as that
used in the current study, and which we have previously
shown does cause up-regulation of [125I]α-Btx binding in adult
rats (Rasmussen and Perry, 2006). Clearly this subtype is less
prone to up-regulation compared to α4β2⁎ (Pauly et al., 1991).
Thismay be a consequence of the relatively lower affinity of α7
receptors to nicotine compared to the α4β2⁎ subtype. A similar
explanation has been advanced for the resistance of α3β4⁎
nAChRs tonicotine-inducedup-regulation (Nguyenet al., 2003;
Dávila-García et al., 2003). However, affinity differences alone
cannot explain all subtype differences in nicotine regulation:
α6⁎nAChRs exhibit affinity for nicotine in the samenanomolar
range as α4β2⁎ nAChRs (Zoli et al., 2002), and this subtype is
either not affected or is down-regulated by chronic nicotine
exposure. The present results demonstrate that this subtype is
unique in otherways aswell. First, it does not demonstrate the
same developmental arc as the α4β2⁎ and α7 subtypes, but
instead shows relatively constant levels from adolescence to
adulthood. Second, its responsiveness to nicotine regulation
shows a different age-dependence than these other two
subtypes: α6⁎ nAChRs are more prone to nicotine-induced
changes in adolescents than in adults. One possible explana-
tion for these differences would be if the subunit composition
of α6⁎ nAChRs differed in the adolescent. We have recently
shown that α6⁎ nAChRs co-expressing the β3 subunit are
resistant to nicotine-induced down-regulation compared to
α6⁎ nAChRs lacking this subunit (Perry et al., 2007).
Because this treatment protocol relies upon initial body
weight for dose calculations, and because adolescents grow at a
faster rate during the two-week dosing period, it was not
surprising to find that by the end of the period, the actual per-
weight dose in adolescents, as well as the corresponding blood
levels of both nicotine and cotinine, were approximately half
that in adults; similar results were reported previously by
Slotkin et al. (Trauth et al., 2000b). The finding that brain
nicotine levels in adults were also roughly twice those in
adolescents is novel. While this difference is unrelated to
differences in receptor expression between age groups, we
cannot rule out that it contributes to differences in responsive-
ness to chronic nicotine exposure. Note, however, that the brain
concentrationswerequite high; even the lower concentration in
adolescent brainwould yield N99%occupancy of both α4β2⁎ and
α6⁎ nAChRs, which suggests that the differences in concentra-tion achievedmaynot be relevant to differential responsiveness
of at least these two high-affinity receptor subtypes.
Our studies do not differentiate between an increased
number of receptors per neuron or an increase in the number
of neurons expressing nAChRs. It is recognized that synaptic
pruning occurs during adolescence (Spear, 2004). The wide-
spread difference in α4β2⁎ and α7 receptors between periado-
lescent and adult brains that we detected could be a result of
such pruning. The age differences in responsiveness to nAChR
up-regulation are more difficult to explain, in part because the
mechanism(s) for such regulation remain elusive. Evidence
from in vitro expression systems suggests an effect of nicotine
on subunit assembly (Kuryatov et al., 2005); it is unclear how
such a process might differ in adolescent brain. A general-
izationof thecurrentdatamightbe thatup-regulation is greater
when initial receptor levels are lower; this suggests a possible
“ceiling” effect on the process. Evidence for a ceiling effect on
nAChR up-regulation has not been seen with in vitro models,
which often demonstrate far greater increases than seen in
vivo. Furthermore, the generalization of less up-regulationwith
higher initial expression is far from uniform across brain
regions. We recently reported that co-expression of α5 with
α4β2⁎nAChRs is associatedwith resistance to nicotine-induced
up-regulation (Mao et al., 2008); as discussed abovewith the α6⁎
nAChR, it is possible that adolescent α4β2⁎ nAChRs demon-
strate a different subunit composition than adults, which could
affect sensitivity to up-regulation by nicotine.
Differences between subtypes in their regulation by
chronic nicotine mean that the overall balance of receptor
subtypes will shift with continued exposure, and presumably
the response pattern to subsequent nicotine exposure. It
should be pointed out that these experiments do not assess
receptor functionality; because nAChRs desensitize with
continued agonist stimulation, it is possible that the rate or
extent of desensitization, or recovery from desensitization,
differs in adult and adolescent animals. We have previously
shown that the increased numbers of α4β2-like receptors
following identical chronic nicotine exposure in adult rats
represent functional receptors, as assayed by 86Rb efflux
(Nguyen et al., 2004), and that the decreased numbers of α6⁎
receptors in striatum were accompanied by a like decrease in
α-CtxMII-sensitive nicotine-stimulated dopamine release
from striatal synaptosomes (Perry et al., 2007).
In conclusion, adolescent rats have a distinct pattern of
nAChR expression, and respond differently to chronic nicotine
exposure, compared to adult rats. A different pattern of CNS
nicotinic receptor expression may play a role in the initiation
of smoking among adolescents. Furthermore, the distinct
pattern of responses of nAChR subtypes to nicotine during
adolescence may contribute to the higher daily consumption
and decreased probability of cessation observed in smokers
who initiate tobacco use during adolescence.4. Experimental procedures
4.1. Materials
[125I]α-conotoxin MII ([125I]α-CtxMII) was synthesized by the
method ofWhiteaker et al. (2000), as adapted by us (Perry et al.,
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was reacted with 10 mCi Na125I (22 μl; Perkin-Elmer Life
Sciences, Boston, MA) using the chloramine-T method. The
reaction mixture was then purified by reversed phase HPLC
and fractions collected. This protocol readily separates
unreacted Tyr0-α-CtxMII from the mono-iodo and di-iodo
forms (Whiteaker et al., 2000); only the mono-iodo form was
utilized, and based on the purification was assumed to be
maximally iodinated (2200 Ci/mmol). [125I]A-85380 and
[125I]αBtx were purchased from Perkin-Elmer Life Sciences
(Shelton, CT). All other chemicals not otherwise mentioned
were obtained from Sigma-Aldrich (St. Louis, MO).
4.2. Animal treatment
Osmotic minipumps (Alzet model 2002; Durect Corporation,
Cupertino, CA) were filled with sterile saline or with nicotine
hydrogen tartrate dissolved in saline, at concentrations
calculated to achieve a dose of 6 mg/kg/day, calculated as
nicotine free base (37 μmol/kg).
Minipumpswere implanted intomale Sprague–Dawley rats
(Hilltop Lab Animals, Scottdale, PA) of two ages, at postnatal
(PN) day 29 or 70–90; eight animals were used for each
treatment group. The period from PN28–40 in rats is typically
labeled periadolescence, that from PN40–52 middle adoles-
cence, and PN52–60 late adolescence; “puberty” generally
occurs during the last days of periadolescence (Spear, 2004).
Thus, our treatment was performed at the early, periadoles-
cent stage. Rats were anesthetized with isoflurane and the
minipumps inserted into a subcutaneous pocket via a small
incision made over the shoulders. While under anesthesia,
animals were administered buprenorphine (0.1 mg/kg, s.c.) for
post-operative pain. The wound was closed with clips and the
area swabbed with antiseptic. After recovery from anesthetic
(10–30 min), animals were returned to individual cages. Four-
teen days after minipump implantation (PN42 for adolescents
PN83–103 for adults), animals were lightly anesthetized with
isoflurane and sacrificed by decapitation.
Because the per-weight dose changes as animals grow, we
used a parallel set of animals to test for the blood and brain
levels of nicotine and cotinine occurring in adolescent and
adult rats treated with nicotine as described. Animals were
weighed prior to sacrifice; trunk blood was collected and
plasma prepared and frozen. Forebrains were then extracted
as previously described (Ghosheh et al., 2001). Briefly, fore-
brains were removed, rinsed in saline and dried, then
homogenized in 3 volumes of ice-cold 1.15% KCl. After
centrifugation for 30 min at 3000 ×g at 4 °C, the supernatant
was treated with 1 ml of 2% w/v ZnSO4 for 1 h at 34 °C to
precipitate proteins. This mixture was then centrifuged at
30,000 ×g for 60 min at 4 °C, after which the supernatant was
removed and frozen.
Concentrations of nicotine and cotinine were determined
in the laboratory of Dr. Neal Benowitz (San Francisco General
Hospital Clinical Pharmacology Laboratory) by gas chromato-
graphy with nitrogen–phosphorus detection (Jacob et al.,
1981), modified for simultaneous extraction of nicotine and
cotinine, and determination using capillary GC (Jacob et al.,
1991). The internal standards, 5-methylnicotine and ortho-
cotinine, were obtained from Dr. Peyton Jacob, III (Division ofClinical Pharmacology of the Department of Medicine, Uni-
versity of California, San Francisco).
Animal use and procedures were approved by the George
Washington University Medical Center Institutional Animal
Care and Use Committee.
4.3. Autoradiography
Following decapitation, brains were rapidly removed and
frozen on dry ice. Frozen coronal brain sections (16 μm) were
cut and mounted onto Superfrost Plus slides (Fisher Scientific,
Newark, DE) and stored at −80 °C until use. For each of the
three autoradiographic experiments described below, sections
from all four treatment groups were incubated together and in
random order, to avoid artifacts from in vitro processing.
[125I]α-CtxMII autoradiographywas adapted from Perry et al.
(2007). Sections were pre-incubated for 15 min in buffer 1
(20 mM HEPES, pH 7.5, 144 mM NaCl, 1.5 mM KCl, 2 mM CaCl2,
1mMMgSO4, 1mM PMSF, 0.1% BSA) at room temperature. This
was followed by incubation for 60 min at room temperature in
buffer 2 (=buffer 1 plus 5 mM EGTA, 5 mM EDTA, 10 μg/ml
aprotinin, 10 μg/ml pepstatin A, 10 μg/ml leupeptin) containing
0.8 nM [125I]α-CtxMII (2200 Ci/mmol). Adjacent sections were
incubated in the same buffer with 100 μM nicotine added to
determine non-specific binding. Slides were then rinsed for
5 min at room temperature in buffer 1, followed by 10 min in
buffer 1 on ice, then sequential dips in ice-cold 5mMHEPES and
H2O followed by rapid air-drying.
Autoradiography for [125I]-5-iodo-3-(2(S)-azetidinylmethoxy)
pyridine ([125I]A-85380) was adapted from Perry et al. (2007)
Sections were first pre-incubated in buffer 1 for 15 min at room
temperature, followed by incubation for 60 min at room
temperature in buffer 1 with 0.6 nM [125I]A-85380 (2200 Ci/
mmol) plus 100 nM unlabeled α-CtxMII. Adjacent sections were
incubated in the same buffer with 100 μM nicotine added to
determine non-specific binding. After incubation, sectionswere
rinsed twice for 5 min in buffer 1, followed by a water dip and
rapid air-drying.
[125I]α-bungarotoxin ([125I]αBtx) binding was adapted from
Rasmussen and Perry (2006). Sections were pre-incubated for
30 min at room temperature in 50 mM Tris–HCl, pH 7.3,
containing 0.1% BSA, then transferred to this same buffer
containing 0.72 nM 125I-α-bungarotoxin (120 Ci/mmol). Adja-
cent sections were incubated in the same buffer with 100 μM
nicotine added to determine non-specific binding. After
120 min incubation at room temperature, sections were then
dipped in ice-cold Tris buffer, then rinsed three times for
10 min in ice-cold buffer, followed by a dip in distilled water
and air-dried.
After overnight desiccation, the sections were apposed to
film (Kodak BioMax MR) for 4 days (for [125I]α-CtxMII and [125I]
A-85380) or 11 days (for [125I]α-bungarotoxin) along with 125I
standards (GE Healthcare, Piscataway, NJ); film was developed
in an automatic developer. Film images were digitized and
quantitative densitometric analysis of binding was done using
the Loats Inquiry digital densitometry system (Loats Associ-
ates, Winchester, MD). Quantification of binding was done by
comparison with standard curves constructed from 125I
standards; regions were identified by comparison with the
rat brain atlas of Paxinos and Watson (2007). Non-specific
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binding in the paired section to calculate specific binding.
While eight animals were used for each treatment group, for
some regions the number of replicates measured per treat-
ment group was less (5–8) due to damaged sections or other
technical considerations.
Log-transformed means of specific binding in individual
brain regions for each radioligand were compared using two-
way ANOVA (SigmaStat 3.5) followed by Holm–Sidak post-hoc
comparison of the four treatment groups; differences were
accepted at p<0.05. To determine the global effects of age and
treatment on binding of each receptor subtype, we used the
general linearmodel (GLM) procedure in SAS (version 8) to test
main effects and interactions for the age and treatment
variables. Due to non-normality of the dependent variables
of the [125I]α-CtxMII binding, even after a log transformation,
the GLM procedure was done on the ranks of the variables.Acknowledgments
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